Amgen Inc. reported after market close Tuesday that despite higher than expected fourth quarter profits, bolstered by strong sales of Enbrel (etanercept), sales of Neupogen (filgrastim) fell 11 percent year over year, driven by the impact of U.S. competition, inventory issues and foreign exchange rates.